Korea's Samsung, SK Hynix Single-Stock Leverage ETFs Churn ₩37 Trillion in Turnover in Four Days, Stoking Overheating Alarms
Single-stock leveraged ETFs on Samsung and SK Hynix racked up ₩37 trillion in turnover within four trading days of their May 27 launch, while Samsung Electronics' market cap crossed USD 1.56 trillion to displace Meta from the global top 10.
- 02
Goldman Sachs Raises KOSPI Target to 12,000 as Korea Posts 300% Earnings Boom, Top Pick in Asia
South Korea's KOSPI closed at 8,801 on June 2 as Goldman Sachs raised its 12-month target to 12,000 — a further 35% upside — citing 300% earnings growth, the sharpest annual profit surge in any Asian market since Korea's own 1999 post-crisis rebound, and a 'Higher for Longer' memory supercycle.
- 03
LIG Defense (079550.KS) Q1 2026: Profit +56%, Cash Sinks 88%
- 04
SK Group Chair Vows to Double HBM Wafer Output in Five Years as Huang Hails Hynix’s USD 1 Trillion Cap
SK Group Chairman Chey Tae-won pledged at Computex 2026 to double SK hynix’s wafer production capacity within five years, warning the global HBM supply crunch will persist through 2030, as Nvidia CEO Jensen Huang hailed SK hynix’s USD 1 trillion market-cap milestone at a bilateral Taipei meeting.
- 05
Samsung (005930.KS) Shows HBM5, Targets SK hynix HBM Lead
- 06
LG Innotek (011070.KS) Q1 2026: Optical Margins Triple as Operating Profit Surges 136%
- 07
Korea Investment Joins Goldman, BofA and Barclays on Carlyle's €7.7 Billion BASF Coatings Deal in Korean Brokerage's Global First
Korea Investment & Securities Co. has secured its first joint lead arranger seat on a global mega-deal, joining Goldman Sachs, Bank of America Securities and Barclays on the roughly €4.5 billion debt package backing Carlyle Group's €7.7 billion acquisition of BASF SE's coatings division.
- 08
Korea Cuts EUV Tool Clearance to 9 Days for Samsung, SK Hynix
South Korea's cabinet on June 2 cut EUV scanner import clearance from 34 days to 9 days, reducing each installation's overhead by 25 days and USD500 million per tool.
- 09
Hanmi Pharmaceutical Signs $1.26 Billion Licensing Deal With Eli Lilly for Rare Bowel-Disease Drug
Hanmi Pharmaceutical has outlicensed sonefpeglutide, a GLP-2 drug candidate, to Eli Lilly in a deal worth up to $1.26 billion, with $75 million paid upfront. The announcement sent Hanmi stock up 9.78% to ₩539,000, while Korea Investment Securities raised its target price to ₩740,000.
- 10
KB Financial (105560.KS) Opens Chairman Succession Early
- 11
Hanwha Systems (272210.KS) Q1 2026: Defense Profit Surges 37% as Austal Stake Loss Flips Net to −₩95.8B
LineVest Daily
Get this wrap in your inbox every morning.
One email before the U.S. open — the earnings, filings, and guidance changes that matter, in plain English. Free.
Subscribe free